Glenmark Pharmaceuticals has launched Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials (SDVs), 5,000 mg/50 mL (100 mg/mL) SDVs and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package.

Glenmark’s Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL), of Fresenius Kabi USA.

According to IQVIA sales data for the 12-month period ending June 2026, the Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL) market achieved annual sales of approximately USD 69.9 million.

Commenting on the launch, Marc Kikuchi, President and Business Head, North America, said, “The launch of Calcium Gluconate Injection USP marks another important step in strengthening Glenmark’s US injectables business and expanding our hospital portfolio. It reflects the disciplined execution of our strategy to build a differentiated and sustainable injectables business–one that addresses institutional needs, supports greater supply resilience and deepens Glenmark’s relevance across the US healthcare system.”